| 產(chǎn)品名稱 | VE 822 |
| 產(chǎn)品貨號 | Axon 2452 CAS [1232416-25-9] MF C24H25N5O3SMW 463.55 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description Selective ATR inhibitor (IC50 values 0.019 μM, 2.6 μM, and 18.1 μM for ATR, ATM, and DNA-PK, respectively) with in vitro and in vivo activity that decreases maintenance of cell-cycle checkpoints and homologous recombination in irradiated cancer cells, and increases persistent DNA damage. VE822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine. References Certificates Categories Extra info E. Fokas et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012 Dec 6;3:e441. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology ATR p53-Tumor Suppression PI3K-Akt-mTOR DNA-damage Response EC 2.7.11.1 Selective ATR inhibitor that decreases survival of pancreatic cancer cells Chemical name 5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine Parent CAS No. [1232416-25-9] Order Size Unit Price Stock 10 mg €110.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
VE 822Axon 2452 CAS [1232416-25-9] MF C24H25N5O3S
Description
Selective ATR inhibitor (IC50 values 0.019 μM, 2.6 μM, and 18.1 μM for ATR, ATM, and DNA-PK, respectively) with in vitro and in vivo activity that decreases maintenance of cell-cycle checkpoints and homologous recombination in irradiated cancer cells, and increases persistent DNA damage. VE822 decreased survival of pancreatic cancer cells but not normal cells in response to XRT or gemcitabine.
Selective ATR inhibitor that decreases survival of pancreatic cancer cells
Chemical name5-(4-(isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine Parent CAS No.[1232416-25-9] |
| 產(chǎn)品資料 |
